Commencement of Cohort 3 in Phase 1/2 MND Trial
Released
Released
Announcement PDF
Commencement of Cohort 3 in Phase 1/2 MND Trial
•
•
•
•
The dosages used for Cohorts 1 and 2 were well tolerated, five patients have passed
the 7-month mark, and no Serious Adverse Events were observed, implying the drug
has a good safety profile
Trial Safety Committee approved Cohort 1 patients to be elevated to Cohort 3 and
receive increased dosage
First two participants (one from each site) received an initial escalated dose of MPL
yesterday, with the final patient expected around 21 June 2023
The analysis evaluating changes in biomarkers and pharmacodynamics is well
underway
9 June 2023 – Perth, Australia: PharmAust Limited (ASX: PAA & PAAO), a clinical-stage
biotechnology company, is pleased to announce the commencement of Cohort 3 dosing in its current
Phase 1/2 trial testing the effects of Monepantel (MPL) in individuals living with motor neurone disease
(MND).
As recently announced, the Trial Safety Committee has approved patients in Cohort 1 to be promoted
to Cohort 3, where they will receive a larger 6mg/kg dose of MPL. In line with expectations, MPL has
displayed an excellent safety profile with no Serious Adverse Events observed and all patients electing
to continue with MPL treatment.
Interim pharmacokinetic study results show that the reformulated MPL tablets developed by PharmAust
specifically for this trial produce steady-state MPL plasma levels within the predetermined therapeutic
range from Day 1. Further, steady-state therapeutic levels of Monepantel Sulphone (MPLS) – the
principal metabolite of MPL – are being reached before Day 8.
The detailed understanding being developed about achieving steady-state MPL / MPLS plasma
concentrations is central to determining the MPL dose required to achieve therapeutic drug
concentrations in a range of human diseases, including cancer.
The decision of all patients from Cohort 1 to move into Cohort 3 is expected to expedite the completion
of Cohort 3 dosing. All patients in Cohort 2 have elected to continue with MPL treatment pending their
promotion to Cohort 4, subject to Trial Safety Committee approval after Cohort 3.
Biomarker analysis
Biomarkers being assessed through the current trial are helpful diagnostic tools in MND that can also
be used to track disease progression and determine the likely course of the disease. Evidence gathered
through the current trial demonstrating MPL’s ability to affect these biomarkers positively will help to
inform the design of subsequent human studies and may support a more rapid approval pathway that
includes TGA and FDA orphan drug designations.
As previously announced, interim analysis of biomarkers and pharmacodynamics through the current
Phase 1/2 study is underway. Three independent Australian institutions are completing these highly
specialised assays to explore how MPL acts on the mTOR signalling pathway in MND patients to slow
disease progression. Biomarker analysis is expected to confirm MPL’s ability to cross the blood-brain
barrier and to aid in clearing protein aggregation, which is the hallmark of neurodegenerative diseases
through the induction of autophagy in nerve cells.
PharmAust Limited ABN 35 094 006 023. Suite 116, 1 Kyle Way, Claremont, Western Australia
Tel: 08 9202 6814 Fax: 08 9467 6111
www.pharmaust.com
It is anticipated that biomarker assays being run at each institution will be completed over the coming
weeks. PharmAust will report the combined analysis of these assays once this information is to hand.
Dr Roger Aston, Executive Chairman of PharmAust, said:
“The analyses of biomarkers, in conjunction with the recently reported pharmacokinetic study results,
are expected to be significant drivers of shareholder value. With good results in the clinic, the company
intends to pursue the fastest possible route to approval for the benefit of MND patients and their
families.”
“We are delighted with trial progress to date and look forward to confirming MPL’s clinical benefits to
MND patients soon.”
The Board authorises this announcement.
Enquiries:
Anusha Aubert
Investor Relations
investorenquiries@pharmaust.com
P +61 (8) 9202 6814
F +61 (8) 9467 6111
W www.pharmaust.com
About PharmAust Limited:
PharmAust Limited is listed on the Australian Securities Exchange (code: PAA) and the Frankfurt Stock Exchange
(code: ECQ). PAA is a clinical-stage company developing therapeutics for both humans and animals. The company
specialises in repurposing marketed drugs lowering the risks and costs of development. These efforts are supported
by PAA’s subsidiary, Epichem, a highly successful contract medicinal chemistry company which generated $3.4
million in sales of goods & services in FY 2022.
PAA’s lead drug candidate is monepantel (MPL), a novel, potent and safe inhibitor of the mTOR pathway – a
pathway having key influences in cancer growth and neurodegenerative diseases. MPL has been evaluated in
Phase 1 clinical trials in humans and Phase 2 clinical trials in dogs. MPL treatment was well-tolerated in humans,
demonstrating preliminary evidence of anticancer activity. MPL demonstrated objective anticancer activity in dogs.
PAA is uniquely positioned to commercialise MPL for treatment of human and veterinary cancers as well as
neurodegenerative disease as it advances a reformulated version of this drug through Phase 1 and 2 clinical trials.
PharmAust Limited ABN 35 094 006 023. Suite 116, 1 Kyle Way, Claremont, Western Australia
Tel: 08 9202 6814 Fax: 08 9467 6111
www.pharmaust.com
Share your feedback
Discover